Logo Logo
Hilfe
Hilfe
Switch Language to English

Gewily, Mohamed ORCID logoORCID: https://orcid.org/0009-0004-4724-3824; Plan, Elodie L. ORCID logoORCID: https://orcid.org/0000-0002-2255-3904; Yousefi, Elham; König, Franz; Posch, Martin ORCID logoORCID: https://orcid.org/0000-0001-8499-8573; Hopfner, Franziska ORCID logoORCID: https://orcid.org/0000-0001-6524-0281; Höglinger, Günter ORCID logoORCID: https://orcid.org/0000-0001-7587-6187 und Karlsson, Mats O. ORCID logoORCID: https://orcid.org/0000-0003-1258-8297 (2024): Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory. In: Movement Disorders [Forthcoming]

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Background : Progressive supranuclear palsy (PSP) is a neurodegenerative, late-onset disease that is challenging in terms of assessment. The Progressive Supranuclear Palsy Rating Scale (PSPRS), a 28-item clinician-reported scale, is the most established clinical outcome assessment method. Recently, the U.S. Food and Drug Administration (FDA) has proposed a subscale of 10 items as an alternative to full PSPRS. Objectives : To quantitatively evaluate and compare the properties of full PSPRS and the FDA subscale using item response theory. To develop a progression model of the disease and assess relative merits of study designs and analysis options. Methods : Data of 979 patients from four interventional trials and two registries were available for analysis. Our investigation was divided into: (1) estimating informativeness of the 28 items; (2) estimating disease progression; and (3) comparing the scales, trial designs, and analysis options with respect to power to detect a clinically relevant treatment effect. Results : PSPRS item scores had a low pairwise correlation (r = 0.17 ± 0.14) and the items irritability, sleep difficulty, and postural tremor were uncorrelated with the other items. The FDA-selected items displayed higher correlation (r = 0.35 ± 0.14) and were the basis for a longitudinal item response model including disease progression. Trial simulations indicated that identification of a disease-modifying treatment effect required less than half the study size if the analysis was based on longitudinal item information compared with total scores at end-of-treatment. Conclusion : A longitudinal item response model based on the FDA-selected PSPRS items is a promising tool in evaluating treatments for PSP.

Dokument bearbeiten Dokument bearbeiten